Pub Date : 2021-01-01DOI: 10.15406/jccr.2021.14.00518
A. Otljanski
,
，
{"title":"Diagnostic and complications of Covid 19 surgical patients","authors":"A. Otljanski","doi":"10.15406/jccr.2021.14.00518","DOIUrl":"https://doi.org/10.15406/jccr.2021.14.00518","url":null,"abstract":"<jats:p>,</jats:p>","PeriodicalId":15200,"journal":{"name":"Journal of Cardiology & Current Research","volume":"116 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87821832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-12-31DOI: 10.15406/JCCR.2020.13.00497
Antonio Filho, Rafael Oliveira Lopes, R. C. Cunha, Juan Jailson Oliveira Almeida Costa, L. Bessa, R. Lima, Alana dos Reis Silva, M. Mercês, Diorlene Oliveira da Silva, Cecília Freitas da Silva Araújo, Nivaldo Menezes Filgueiras Filho, L. Magalhães
Arterial hypertension (AH) is the most common disease in adulthood. In Brazil, the estimated prevalence of SAH in 2018 was 24.7% in adults and above 60.9% in the elderly population.1 Frequently associated with metabolic disorders, functional or structural changes in target organs, and aggravated by the presence of other risk factors (RF), such as dyslipidemia, abdominal obesity, glucose intolerance and diabetes mellitus (DM).2,3 Although SAH is directly related to age, some factors predispose the disease at an early stage, such as obesity.,3 DM4 and physical inactivity,5 which are directly linked to oxidative tissue stress and chronic inflammation. In addition, it causes a high social cost and is the main risk factor for cardiovascular mortality.
{"title":"Prevalence of hypertension, arterial stiffness and risk factor association","authors":"Antonio Filho, Rafael Oliveira Lopes, R. C. Cunha, Juan Jailson Oliveira Almeida Costa, L. Bessa, R. Lima, Alana dos Reis Silva, M. Mercês, Diorlene Oliveira da Silva, Cecília Freitas da Silva Araújo, Nivaldo Menezes Filgueiras Filho, L. Magalhães","doi":"10.15406/JCCR.2020.13.00497","DOIUrl":"https://doi.org/10.15406/JCCR.2020.13.00497","url":null,"abstract":"Arterial hypertension (AH) is the most common disease in adulthood. In Brazil, the estimated prevalence of SAH in 2018 was 24.7% in adults and above 60.9% in the elderly population.1 Frequently associated with metabolic disorders, functional or structural changes in target organs, and aggravated by the presence of other risk factors (RF), such as dyslipidemia, abdominal obesity, glucose intolerance and diabetes mellitus (DM).2,3 Although SAH is directly related to age, some factors predispose the disease at an early stage, such as obesity.,3 DM4 and physical inactivity,5 which are directly linked to oxidative tissue stress and chronic inflammation. In addition, it causes a high social cost and is the main risk factor for cardiovascular mortality.","PeriodicalId":15200,"journal":{"name":"Journal of Cardiology & Current Research","volume":"7 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84179511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-12-31DOI: 10.15406/JCCR.2020.13.00496
V. Tómicic, Krasna Tomicic
The coronavirus (CoV) belongs to a family of viruses that can cause a variety of clinical presentations, including catarrhal symptoms, cough, fever, respiratory distress, and conditions such as pneumonia, among others. Worldwide, more than 29million confirmed COVID-19 cases have been reported with 926,544 deaths, 51% of which correspond to the Americas. Careful observations have hypothesized that patients present with different clinical patterns that depend mainly on 3 factors: (1) severity of infection and host response, physiological reserve and comorbidities (2) ventilatory response to hypoxemia and (3) the delay from the onset of symptoms and evaluation in the hospital. About 4.4% of patients require IMV during the first 14days after symptoms start and reach a high mortality rate. This disease mainly shows two behaviors related to time: phenotype L, Low elastance [high compliance] and phenotype H, High elastance [low compliance]. The L phenotype, with low V/Q ratio, low lung weight, and low potential for recruitment occurs early in the disease. The H phenotype is characterized by low compliance, high shunt levels, high lung weight, and high potential for recruitment, and it usually manifests within 7days. In our experience, there would be a third group that progresses to early pulmonary fibrosis characterized by very low compliance, making the ventilatory process exceedingly difficult (they require a low PEEP [6-8cmH2O] and very low VT 4-6ml/kg predicted body weight. These patients retain CO2 and may require extracorporeal CO2 removal (ECCO2R). Although SARS CoV-2 pneumonia does not evolve as a classic ARDS, emerging evidence suggests that ARDS associated with CoVID-19 evolves with acute respiratory failure and lung mechanics typical of a historical ARDS. One aspect that could differentiate them is related to the levels of D-Dimer (DD). The subgroup of patients with DD concentrations higher than the median and a static compliance equal to or less than the median (HDLC: High D-dimers, low compliance) have at 28-days mortality higher than the rest of the groups, such as: high DD with high compliance (HDHC), low DD with low compliance (LDLC) and low DD with high compliance (LDHC). The 28-day mortality for HDLC was 56% and 27% for LDHC Up to the present time, IMV with open lung approach (OLA) has not been shown to reduce mortality; it has only accomplished to improve oxygenation and reduce driving pressure, without exerting deleterious effects such as barotrauma or increases in mortality.
{"title":"Mechanical ventilation in patients with SARS-CoV-2 pneumonia","authors":"V. Tómicic, Krasna Tomicic","doi":"10.15406/JCCR.2020.13.00496","DOIUrl":"https://doi.org/10.15406/JCCR.2020.13.00496","url":null,"abstract":"The coronavirus (CoV) belongs to a family of viruses that can cause a variety of clinical presentations, including catarrhal symptoms, cough, fever, respiratory distress, and conditions such as pneumonia, among others. Worldwide, more than 29million confirmed COVID-19 cases have been reported with 926,544 deaths, 51% of which correspond to the Americas. Careful observations have hypothesized that patients present with different clinical patterns that depend mainly on 3 factors: (1) severity of infection and host response, physiological reserve and comorbidities (2) ventilatory response to hypoxemia and (3) the delay from the onset of symptoms and evaluation in the hospital. About 4.4% of patients require IMV during the first 14days after symptoms start and reach a high mortality rate. This disease mainly shows two behaviors related to time: phenotype L, Low elastance [high compliance] and phenotype H, High elastance [low compliance]. The L phenotype, with low V/Q ratio, low lung weight, and low potential for recruitment occurs early in the disease. The H phenotype is characterized by low compliance, high shunt levels, high lung weight, and high potential for recruitment, and it usually manifests within 7days. In our experience, there would be a third group that progresses to early pulmonary fibrosis characterized by very low compliance, making the ventilatory process exceedingly difficult (they require a low PEEP [6-8cmH2O] and very low VT 4-6ml/kg predicted body weight. These patients retain CO2 and may require extracorporeal CO2 removal (ECCO2R). Although SARS CoV-2 pneumonia does not evolve as a classic ARDS, emerging evidence suggests that ARDS associated with CoVID-19 evolves with acute respiratory failure and lung mechanics typical of a historical ARDS. One aspect that could differentiate them is related to the levels of D-Dimer (DD). The subgroup of patients with DD concentrations higher than the median and a static compliance equal to or less than the median (HDLC: High D-dimers, low compliance) have at 28-days mortality higher than the rest of the groups, such as: high DD with high compliance (HDHC), low DD with low compliance (LDLC) and low DD with high compliance (LDHC). The 28-day mortality for HDLC was 56% and 27% for LDHC Up to the present time, IMV with open lung approach (OLA) has not been shown to reduce mortality; it has only accomplished to improve oxygenation and reduce driving pressure, without exerting deleterious effects such as barotrauma or increases in mortality.","PeriodicalId":15200,"journal":{"name":"Journal of Cardiology & Current Research","volume":"26 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77171254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-12-19DOI: 10.15406/JCCR.2020.13.00495
O. Sebastián, J. Calvo, Manuela Dobón-Rebollo, Irene Amarilla, Nuria Fernández, Luis Ignacio Sancho, I. Cuesta, E. Franco-García, A. Pérez, L. Lacalle
Background: Idarucizumab is the only reversal agent specifically targeting dabigatran anticoagulation effect. Real-world evidence for idarucizumab in Spain is limited. Objectives: To assess idarucizumab management and results according to the routine clinical practice in emergency situations in Aragon (Spain). Methods: Observational, retrospective, multicentre study in Aragon (Spain). All patients that received idarucizumab (January 2016 - October 2019) for urgent reversal (major bleeding or emergency surgery) were included. Reversal effect was based on the activated Partial Thromboplastin Time (aPTT) in the first 24h. Results: During the study period, thirty patients needed idarucizumab reversal in Aragon: 22 (73.3%) emergency surgeries, 7 (23.3%) major bleedings and 1 off-label use. Most patients were male (63.3%), aged (70.0% ≥75y-o) and showed mild/moderate renal impairment (80.0%). A high proportion of patients (66.7%) used dabigatran 110 mg (twice daily). Complete reversal (aPTT ≤40 seconds) was shown in 70.0% of the patients (85.7% major bleeding; 63.6% emergency surgery). Haemostasis was restored mainly in aged patients (81% in patients ≥75y-o), female (81.8%) and dabigatran reduced dose users (75.0%). Adverse events were shown in two patients (6.7%), none of them thrombosis-related. Since no thromboembolism was shown, according to clinical criteria, all patients could be considered as successfully reverted. Conclusions: Idarucizumab demonstrated effective reversal of dabigatran in ≥70% of the emergency situations linked to anticoagulation reversal need in Aragon (Spain). The clinical use of idarucizumab was safe and conducted according to the authorized label, although it would be recommendable the development of standardized hospital protocols to guarantee an optimal drug use.
{"title":"Real world use of idarucizumab for dabigatran reversal in Aragón (Spain)","authors":"O. Sebastián, J. Calvo, Manuela Dobón-Rebollo, Irene Amarilla, Nuria Fernández, Luis Ignacio Sancho, I. Cuesta, E. Franco-García, A. Pérez, L. Lacalle","doi":"10.15406/JCCR.2020.13.00495","DOIUrl":"https://doi.org/10.15406/JCCR.2020.13.00495","url":null,"abstract":"Background: Idarucizumab is the only reversal agent specifically targeting dabigatran anticoagulation effect. Real-world evidence for idarucizumab in Spain is limited. Objectives: To assess idarucizumab management and results according to the routine clinical practice in emergency situations in Aragon (Spain). Methods: Observational, retrospective, multicentre study in Aragon (Spain). All patients that received idarucizumab (January 2016 - October 2019) for urgent reversal (major bleeding or emergency surgery) were included. Reversal effect was based on the activated Partial Thromboplastin Time (aPTT) in the first 24h. Results: During the study period, thirty patients needed idarucizumab reversal in Aragon: 22 (73.3%) emergency surgeries, 7 (23.3%) major bleedings and 1 off-label use. Most patients were male (63.3%), aged (70.0% ≥75y-o) and showed mild/moderate renal impairment (80.0%). A high proportion of patients (66.7%) used dabigatran 110 mg (twice daily). Complete reversal (aPTT ≤40 seconds) was shown in 70.0% of the patients (85.7% major bleeding; 63.6% emergency surgery). Haemostasis was restored mainly in aged patients (81% in patients ≥75y-o), female (81.8%) and dabigatran reduced dose users (75.0%). Adverse events were shown in two patients (6.7%), none of them thrombosis-related. Since no thromboembolism was shown, according to clinical criteria, all patients could be considered as successfully reverted. Conclusions: Idarucizumab demonstrated effective reversal of dabigatran in ≥70% of the emergency situations linked to anticoagulation reversal need in Aragon (Spain). The clinical use of idarucizumab was safe and conducted according to the authorized label, although it would be recommendable the development of standardized hospital protocols to guarantee an optimal drug use.","PeriodicalId":15200,"journal":{"name":"Journal of Cardiology & Current Research","volume":"89 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78979023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-12-17DOI: 10.15406/JCCR.2020.13.00494
M. Hamad, M. Buheji, Sufian Khalid Mohammed Nor, E. V. Popova, Abdul Jabba
{"title":"Influences of meteorological factors on COVID.19 pandemic: prevalence and outcomesMosab Nouraldein Mohammed Hamad,1,2 Mohamed Buheji,3 Sufian Khalid Mohammed Nor,4 Elizaveta V Popova,5 Abdul Jabba6","authors":"M. Hamad, M. Buheji, Sufian Khalid Mohammed Nor, E. V. Popova, Abdul Jabba","doi":"10.15406/JCCR.2020.13.00494","DOIUrl":"https://doi.org/10.15406/JCCR.2020.13.00494","url":null,"abstract":"","PeriodicalId":15200,"journal":{"name":"Journal of Cardiology & Current Research","volume":"34 1","pages":"150-152"},"PeriodicalIF":0.0,"publicationDate":"2020-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74034445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-12-03DOI: 10.15406/jccr.2020.13.00493
Pratibha Gupta, M. Collins
Public health significance: Many racial health disparities exist in this country, and a primary goal of public health, as a whole, is to decrease these disparities (U.S. Department of Health and Human Services [HHS].1 Public health professionals have worked tirelessly in low-income areas and those with residents of racial minorities in an attempt to decrease the health disparities between these populations and the healthier people within higher socioeconomic groups. One opportunity that public health has yet to take advantage of is the Historically Black College University (HBCU); a high population of resident African American students at H.B. is the best, convenient way to access public health study. These students are at higher risk of morbidity and mortality from cardiovascular disease (CVD), diabetes, and other lifestyle-associated diseases. These young AfricanAmericans are taking the first steps in establishing themselves as independent adults. Providing evidence-based health promotion recommendations and education for HBCU students could help them develop healthier lifestyles during an essential stage of their adult lives and have lasting benefits.
{"title":"Assessment of cardiovascular health, sleep habits, and diets among college students by utilizing public health screening tools","authors":"Pratibha Gupta, M. Collins","doi":"10.15406/jccr.2020.13.00493","DOIUrl":"https://doi.org/10.15406/jccr.2020.13.00493","url":null,"abstract":"Public health significance: Many racial health disparities exist in this country, and a primary goal of public health, as a whole, is to decrease these disparities (U.S. Department of Health and Human Services [HHS].1 Public health professionals have worked tirelessly in low-income areas and those with residents of racial minorities in an attempt to decrease the health disparities between these populations and the healthier people within higher socioeconomic groups. One opportunity that public health has yet to take advantage of is the Historically Black College University (HBCU); a high population of resident African American students at H.B. is the best, convenient way to access public health study. These students are at higher risk of morbidity and mortality from cardiovascular disease (CVD), diabetes, and other lifestyle-associated diseases. These young AfricanAmericans are taking the first steps in establishing themselves as independent adults. Providing evidence-based health promotion recommendations and education for HBCU students could help them develop healthier lifestyles during an essential stage of their adult lives and have lasting benefits.","PeriodicalId":15200,"journal":{"name":"Journal of Cardiology & Current Research","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79045406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-10-30DOI: 10.20960/angiologia.00151
Andres Ramírez Vélez, S. Valencia, N. Jaramillo, S. Echeverri
2020 Summary A fenestrated endovascular repair of a pararenal abdominal aortic aneurysm was complicated by disconnection of a bridging renal stent and successfully managed endovascularly.
对肾旁腹主动脉瘤进行开窗血管内修复，并断开了桥式肾支架，并成功地进行了血管内处理。
{"title":"Endovascular management of a disconnected bridging stent during fenestrated endovascular aortic repair","authors":"Andres Ramírez Vélez, S. Valencia, N. Jaramillo, S. Echeverri","doi":"10.20960/angiologia.00151","DOIUrl":"https://doi.org/10.20960/angiologia.00151","url":null,"abstract":"2020 Summary A fenestrated endovascular repair of a pararenal abdominal aortic aneurysm was complicated by disconnection of a bridging renal stent and successfully managed endovascularly.","PeriodicalId":15200,"journal":{"name":"Journal of Cardiology & Current Research","volume":"11 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74867979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-10-17DOI: 10.15406/JCCR.2020.13.00491
D. Azboy, Zeki Temizturk, F. S. Türker
Introduction: We investigated the effects of pharmacomechanical therapy (PMT) on post- thrombotic syndrome; which is a late complication in patients with acute and subacute iliofemoral deep venous thrombosis (DVT). Method: A total of 25 (14 males, 11 females) patients; who were diagnosed with acute and subacute iliofemoral DVT and treated in the cardiovascular surgery clinic of Elazığ Training and Research Hospital from September 2016 to November 2018, were evaluated retrospectively by using data in the hospital’s digital archiving system. The effects of PMT applied to the patients were evaluated on the development of post-thrombotic syndrome and venous reflux as the late complications. Results : No complications occurred in patients during the intervention and therapeutic processes. After the treatment, patency and flow were achieved in 92% of the patients and significant reductions in the subjective complaints were observed in 88% of the patients. Maintained patency ratios of 92%, 84%, and 80% were confirmed in the first month, the first year, and the second year, respectively, by venous doppler ultrasonography. Post- thrombotic syndrome did not develop in 80% of the patients clinically. Discussion : We suggest that PMT is a favourable treatment option for the prevention of the development of post-thrombotic syndrome and venous reflux as the late complications in acute and subacute proximal DVT patients.
{"title":"Effects of pharmacomechanical therapy on late complications in deep venous thrombosis","authors":"D. Azboy, Zeki Temizturk, F. S. Türker","doi":"10.15406/JCCR.2020.13.00491","DOIUrl":"https://doi.org/10.15406/JCCR.2020.13.00491","url":null,"abstract":"Introduction: We investigated the effects of pharmacomechanical therapy (PMT) on post- thrombotic syndrome; which is a late complication in patients with acute and subacute iliofemoral deep venous thrombosis (DVT). Method: A total of 25 (14 males, 11 females) patients; who were diagnosed with acute and subacute iliofemoral DVT and treated in the cardiovascular surgery clinic of Elazığ Training and Research Hospital from September 2016 to November 2018, were evaluated retrospectively by using data in the hospital’s digital archiving system. The effects of PMT applied to the patients were evaluated on the development of post-thrombotic syndrome and venous reflux as the late complications. Results : No complications occurred in patients during the intervention and therapeutic processes. After the treatment, patency and flow were achieved in 92% of the patients and significant reductions in the subjective complaints were observed in 88% of the patients. Maintained patency ratios of 92%, 84%, and 80% were confirmed in the first month, the first year, and the second year, respectively, by venous doppler ultrasonography. Post- thrombotic syndrome did not develop in 80% of the patients clinically. Discussion : We suggest that PMT is a favourable treatment option for the prevention of the development of post-thrombotic syndrome and venous reflux as the late complications in acute and subacute proximal DVT patients.","PeriodicalId":15200,"journal":{"name":"Journal of Cardiology & Current Research","volume":"37 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84093501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-10-13DOI: 10.15406/JCCR.2020.13.00490
S. Mehta, D. Vieira, S. Quintero, D. B. Daher, Floralba Duka, Hudson Franca, Jhonny A. Bonilla, A. Molnar, Cătălin Molnar, D. Zerpa, María Fernanda Fleming Díaz
In 1910, Abraham Flexner published The Flexner Report. After visiting 155 medical schools across the United States and Canada, he established the biomedical model as the gold standard of medical training.1 Among other things, he created a standardized four-year curriculum, recommended a minimum qualification for admittance, and establishes an accreditation process.2 Previous to his report, the majority of medical schools had been founded merely for profit reasons and thus went about their business without any set of rules for admission or accreditation. Flexner’s influence still guides the current curricular reform, and more than a century later, we still believe the fundamental aims proposed by him are relevant. However, we must also consider that to restructure today’s education track optimally, it is necessary to embrace new technologies.
{"title":"Redefining medical education by boosting curriculum with artificial intelligence knowledge","authors":"S. Mehta, D. Vieira, S. Quintero, D. B. Daher, Floralba Duka, Hudson Franca, Jhonny A. Bonilla, A. Molnar, Cătălin Molnar, D. Zerpa, María Fernanda Fleming Díaz","doi":"10.15406/JCCR.2020.13.00490","DOIUrl":"https://doi.org/10.15406/JCCR.2020.13.00490","url":null,"abstract":"In 1910, Abraham Flexner published The Flexner Report. After visiting 155 medical schools across the United States and Canada, he established the biomedical model as the gold standard of medical training.1 Among other things, he created a standardized four-year curriculum, recommended a minimum qualification for admittance, and establishes an accreditation process.2 Previous to his report, the majority of medical schools had been founded merely for profit reasons and thus went about their business without any set of rules for admission or accreditation. Flexner’s influence still guides the current curricular reform, and more than a century later, we still believe the fundamental aims proposed by him are relevant. However, we must also consider that to restructure today’s education track optimally, it is necessary to embrace new technologies.","PeriodicalId":15200,"journal":{"name":"Journal of Cardiology & Current Research","volume":"18 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87157148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-10-07DOI: 10.15406/jccr.2020.13.00489
M. Amiri
Cardiovascular disease (CVD) is still the leading cause of morbidity and mortality worldwide despite huge improvements in the science. The original concept on which lipids have to be accumulated and which lipids must remove in order to achieve the ideal disease prevention, has been changed into the new concept on the mechanisms of lipid movement between lipoproteins, cells and organelles involved in CVD.1
{"title":"Which statin we should use?","authors":"M. Amiri","doi":"10.15406/jccr.2020.13.00489","DOIUrl":"https://doi.org/10.15406/jccr.2020.13.00489","url":null,"abstract":"Cardiovascular disease (CVD) is still the leading cause of morbidity and mortality worldwide despite huge improvements in the science. The original concept on which lipids have to be accumulated and which lipids must remove in order to achieve the ideal disease prevention, has been changed into the new concept on the mechanisms of lipid movement between lipoproteins, cells and organelles involved in CVD.1","PeriodicalId":15200,"journal":{"name":"Journal of Cardiology & Current Research","volume":"14 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75608608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：